Swarajya

Our View
HeadlinesMagazineVideosBooksस्वराज्यEconomyCultureEvents
User Profile
Subscribe
Swarajya
Subscribe
  • Our View
  • Headlines
  • Magazine
Swarajya
  • Politics
  • Economics
  • Business
  • Culture
  • Books & Ideas
  • World
  • Defence
  • Energy & Infrastructure
  • Science
  • Technology
  • Heritage
  • Videos
  • Podcasts
  • Archives
  • Blogs
  • News Brief
  • Subscriber login
  • Politics
  • Economics
  • Business
  • Culture
  • Books & Ideas
  • World
  • Defence
  • Energy & Infrastructure
  • Science
  • Technology
  • Heritage
  • Videos
  • Podcasts
  • Archives
  • Blogs
  • News Brief

BioNTech

Pfizer COVID-19 Vaccine Produces Less Antibodies Against Delta Variant Of Coronavirus, Finds Study Published In Lancet
Pfizer COVID-19 Vaccine Produces Less Antibodies Against Delta Variant Of Coronavirus, Finds Study Published In LancetIANSJun 4, 2021 02:38 PM +05:30 IST
German Company BioNTech To Build First mRNA Manufacturing Facility In Singapore
German Company BioNTech To Build First mRNA Manufacturing Facility In SingaporeIANSMay 10, 2021 04:25 PM +05:30 IST
Pfizer To Supply Its Covid-19 Vaccine Only Through Government Channels In India: Report
Pfizer To Supply Its Covid-19 Vaccine Only Through Government Channels In India: ReportSwarajya StaffApr 22, 2021 09:43 AM +05:30 IST
Pfizer-BioNTech Covid-19 Vaccine Effective Against Highly Infectious Coronavirus Variant Discovered In UK, Finds Study
Pfizer-BioNTech Covid-19 Vaccine Effective Against Highly Infectious Coronavirus Variant Discovered In UK, Finds StudySwarajya StaffJan 21, 2021 12:16 PM +05:30 IST
First Adverse Reaction Of Pfizer & BioNTech's COVID-19 Vaccine Recorded In Finland
First Adverse Reaction Of Pfizer & BioNTech's COVID-19 Vaccine Recorded In FinlandSwarajya StaffJan 3, 2021 02:36 PM +05:30 IST
'Covid-19 Virus Will Stay With Us For Next Ten Years': BioNTech CEO
'Covid-19 Virus Will Stay With Us For Next Ten Years': BioNTech CEO IANSDec 26, 2020 01:41 PM +05:30 IST
Covid Vaccine 'Highly Likely' To Work On UK Variant, Can Adapt It In 6 Weeks To Tackle New Strain If Needed:  BioNTech CEO
Covid Vaccine 'Highly Likely' To Work On UK Variant, Can Adapt It In 6 Weeks To Tackle New Strain If Needed: BioNTech CEO Swarajya StaffDec 22, 2020 06:13 PM +05:30 IST
Pfizer And BioNTech SE To Seek  Emergency Use Approval From  US FDA For Covid-19 Vaccine
Pfizer And BioNTech SE To Seek Emergency Use Approval From US FDA For Covid-19 VaccineSwarajya StaffNov 20, 2020 06:42 PM +05:30 IST
Covid-19 Vaccine Developed By Pfizer-BioNTech Offers 90 Per Cent Protection Against Coronavirus Infection
Covid-19 Vaccine Developed By Pfizer-BioNTech Offers 90 Per Cent Protection Against Coronavirus InfectionSwarajya StaffNov 9, 2020 06:17 PM +05:30 IST
Pfizer And BioNTech Announce Plan To Expand Phase 3 Covid-19 Vaccine Trial By 50% To 44000 Participants
Pfizer And BioNTech Announce Plan To Expand Phase 3 Covid-19 Vaccine Trial By 50% To 44000 ParticipantsSwarajya StaffSep 13, 2020 05:17 PM +05:30 IST
A Tale Of Three Potential Vaccines – How They Stack Up In The Race For Coronavirus Prevention
A Tale Of Three Potential Vaccines – How They Stack Up In The Race For Coronavirus PreventionKaran KambleJul 24, 2020 12:49 PM +05:30 IST
A Day After Encouraging Phase I/II Clinical Trial, Pfizer-BioNTech Announces A $1.95 Billion Covid-19 Vaccine Order From U.S. Government
A Day After Encouraging Phase I/II Clinical Trial, Pfizer-BioNTech Announces A $1.95 Billion Covid-19 Vaccine Order From U.S. GovernmentSwarajya StaffJul 22, 2020 05:55 PM +05:30 IST
Covid-19 Vaccine Could Be Ready By October End, Claims Pharma Major Pfizer’s CEO
Covid-19 Vaccine Could Be Ready By October End, Claims Pharma Major Pfizer’s CEOIANSMay 30, 2020 01:06 PM +05:30 IST
Load More

About Swarajya

Swarajya - a big tent for liberal right of centre discourse that reaches out, engages and caters to the new India.

editor@swarajyamag.com

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Fact Check
  • Gift Swarajya
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Participate

  • Contact Us
  • Write for us
  • Style Guide
  • Advertise
  • Jobs

Stay Connected

  • Artboard 2 Copy 6Created with Sketch.Artboard 2 Copy 10Created with Sketch.Artboard 2 Copy 7Created with Sketch.Artboard 2 Copy 9Created with Sketch.
Copyright: Swarajya. All Rights Reserved.
Powered by Quintype